Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

v3.20.1
Stockholders' Equity (Tables)
3 Months Ended
Mar. 31, 2020
Stockholders' Equity Note [Abstract]  
Preferred Stock Conversion calculation, Series H
Number of Series H Preferred Stock outstanding     8  
Multiplied by the stated value   $ 154  
Equals the gross stated value   $ 1,232  
Divided by the conversion price   $ 36.96  
Equals the convertible shares of common stock     33  
Multiplied by the fair market value of common stock at March 31, 2020   $ 0.45  
Equals the payment   $ 15  
Preferred Stock Conversion calculation, Series H-3
Number of Series H-3 Preferred Stock outstanding     2,189  
Multiplied by the stated value   $ 138  
Equals the gross stated value   $ 302,082  
Divided by the conversion price   $ 33.12  
Equals the convertible shares of common stock     9,121  
Multiplied by the fair market value of common stock at March 31, 2020   $ 0.45  
Equals the payment   $ 4,104  
Preferred Stock Conversion calculation, Series H-4
Number of Series H-4 Preferred Stock outstanding     5,028  
Multiplied by the stated value   $ 235.50  
Equals the gross stated value   $ 1,184,094  
Divided by the conversion price   $ 2.826  
Equals the convertible shares of common stock     419,000  
Multiplied by the fair market value of common stock at March 31, 2020   $ 0.45  
Equals the payment   $ 188,550  
Preferred Stock Conversion calculation, Series H-6
Number of Series H-6 Preferred Stock outstanding     29,822  
Multiplied by the stated value   $ 72.00  
Equals the gross stated value   $ 2,147,184  
Divided by the conversion price   $ 0.72  
Equals the convertible shares of common stock     2,982,200  
Multiplied by the fair market value of common stock at March 31, 2020   $ 0.45  
Equals the payment   $ 1,341,990  
Schedule of share-based compensation, stock options, activity
    Shares Underlying Options     Weighted Average Exercise Price     Weighted Average Remaining Contractual Life (years)     Aggregate Intrinsic Value  
Outstanding at December 31, 2019     380,396     $ 14.43       6.84       -  
Expired     (73,194 )     35.53       -          
Outstanding at March 31, 2020     307,202     $ 9.39       8.20       -  
Schedule of share-based compensation
    Three Months ended March 31,  
    2020     2019  
Research and development     3,758       3,717  
Selling, general and administrative     45,586       484,240  
Total $     49,344     $ 487,957  
Schedule of common stock warrant activity
    Shares Underlying Warrants     Weighted Average Exercise Price     Weighted Average Remaining Contractual Life (years)     Aggregate Intrinsic Value  
Outstanding at December 31, 2019     4,300,560     $ 1.77       5.06       -  
Granted     -       -       -       -  
Exercised/Forfeited     -       -       -       -  
Outstanding at March 31, 2020     4,300,560     $ 1.77       4.81       -